Title : Data Integrity in Gmp Environments: Implementing Alcoa+ for Reliable, Defensible Quality Decisions

Ensuring robust data integrity is fundamental to maintaining product quality, protecting patient safety, and meeting global regulatory expectations. This presentation outlines a practical, phase-gated framework for embedding ALCOA+ principles—Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available—into pharmaceutical quality systems. The approach begins with process mapping of data flows across manufacturing, laboratory, and computerized systems to identify high-risk points for transcription errors, metadata gaps, and undocumented changes. Next, a structured assessment tool is introduced to evaluate alignment with ALCOA+ requirements, covering electronic audit trails, hybrid documentation controls, user access governance, and data-review workflows.

Implementation strategies emphasize simplicity and effectiveness: strengthening contemporaneous documentation practices, designing checks to ensure traceability of entries, enforcing version control, and deploying periodic review of electronic logs to detect anomalies. The model incorporates human-factors concepts—cognitive load, unclear instructions, and interface usability—that frequently contribute to data-integrity failures. Realistic case examples illustrate how inconsistent entries, missing metadata, and delayed recordings can compromise batch disposition and regulatory compliance, and how targeted interventions can reduce these risks.

A practical set of data-integrity metrics is proposed, including audit-trail review cycle time, attributable-error recurrence, hybrid-record reduction, and right-first-time documentation. The session equips attendees with a scalable toolkit for strengthening ALCOA+ adoption, improving inspection readiness, and enabling reliable, science-based decision-making. This framework is designed for QA, QC, manufacturing, and digital-quality stakeholders seeking to enhance data governance without adding unnecessary procedural complexity.

Sushant Kulkarni is a Senior Manager, QA Operations, at clinical stage biotechnology company and is specializing in GMP compliance, deviation investigations, and supplier quality systems. He has reviewed manuscripts for Molecular Therapy and ASQ’s Quality Progress, and serves on the 2026 National Biotechnology Conference Abstract Screening Committee. Sushant’s work focuses on risk based qualification, inspection readiness, and data driven CAPA effectiveness. He has led cross functional quality initiatives that streamline decision making and strengthen compliance without adding complexity. He presents in a personal capacity; views are his own.